Yes, Wegovy Is Approved for Weight Loss
Wegovy (semaglutide) is FDA-approved specifically for chronic weight management in adults with obesity or overweight with weight-related conditions like hypertension, type 2 diabetes, or high cholesterol. It's a once-weekly injection that mimics GLP-1 hormones to reduce appetite and slow gastric emptying, leading to sustained weight loss of 15-20% on average in clinical trials.[1][2]
How Does Wegovy Differ from Ozempic?
Wegovy and Ozempic both contain semaglutide but at different doses—Wegovy goes up to 2.4 mg weekly for weight loss, while Ozempic maxes at 2 mg for type 2 diabetes. Off-label Ozempic use for weight loss is common due to shortages, but Wegovy is the labeled option for obesity without diabetes.[1][3]
Who Qualifies for Wegovy?
Eligibility requires BMI ≥30 (obesity) or ≥27 (overweight) plus a comorbidity. It's not for cosmetic weight loss or short-term use. Doctors assess via lifestyle history; insurance often covers if criteria match, though prior authorization is typical.[2][4]
What Results Can Users Expect?
In STEP trials, patients lost 12-15% body weight over 68 weeks versus 2-3% on placebo, with greater loss when paired with diet and exercise. Maintenance requires ongoing use—stopping leads to partial regain.[1][5]
Common Side Effects and Risks
Nausea, diarrhea, vomiting, and constipation affect over 40% initially but often fade. Serious risks include pancreatitis, gallbladder issues, and thyroid tumors (boxed warning). It's not for those with medullary thyroid cancer history or multiple endocrine neoplasia syndrome.[2][6]
Wegovy vs. Other Weight Loss Drugs
| Drug | Active Ingredient | Avg. Weight Loss | Cost (Monthly, Cash) | Key Notes |
|------|-------------------|------------------|-----------------------|-----------|
| Wegovy | Semaglutide | 15-20% | $1,300-$1,700 | Highest efficacy; supply issues |
| Zepbound | Tirzepatide | 20-22% | $1,000-$1,300 | Dual GLP-1/GIP; diabetes version Mounjaro |
| Saxenda | Liraglutide | 5-10% | $1,300 | Daily injection; older GLP-1 |
| Phentermine | Various | 5-10% | $20-$100 | Short-term oral; stimulant-like |
Zepbound edges out Wegovy in head-to-head data, but both outperform older options.[5][7]
Cost, Access, and Insurance Coverage
List price is $1,349/month without insurance. Novo Nordisk offers savings cards capping copays at $25 for eligible commercially insured patients (up to 13 fills). Medicare covers for obesity in some cases post-2024 rules; shortages persist into 2025.[4][8]
Patent Status and Generic Timeline
Wegovy's key patents expire in 2030-2032, with Novo defending against challenges. No generics until then; biosimilar semaglutide development is underway but faces hurdles.[9]
[1]: FDA.gov - Wegovy Label
[2]: NovoNordisk.com - Wegovy Prescribing Info
[3]: NEJM.org - STEP 1 Trial
[4]: CMS.gov - Medicare Coverage for Anti-Obesity Meds
[5]: JAMA - Semaglutide Trials Meta-Analysis
[6]: FDA.gov - Wegovy Safety Warnings
[7]: Lilly.com - Zepbound Data
[8]: NovoCare.com - Wegovy Savings
[9]: DrugPatentWatch.com - Wegovy Patents